Adicet Bio Announces Reverse Stock Split

Core Viewpoint - Adicet Bio, Inc. has announced a one-for-16 reverse stock split of its common stock to comply with Nasdaq listing requirements, effective December 30, 2025 [1][6]. Group 1: Reverse Stock Split Details - The reverse stock split will combine every sixteen shares of common stock into one share, reducing the outstanding shares from approximately 153.3 million to about 9.6 million [3]. - The par value per share will remain unchanged, and the total number of authorized shares will stay at 300 million, increasing the shares available for future issuance [3]. - Proportional adjustments will be made to equity incentive plans, stock options, and outstanding warrants to reflect the reverse stock split [4]. Group 2: Implementation and Impact - The reverse stock split will take effect at 12:01 a.m. Eastern Time on December 30, 2025, with trading on a split-adjusted basis commencing on the same day [2]. - Stockholders will not need to take any action, as the changes will be reflected in their accounts automatically [6]. - The primary goal of the reverse stock split is to help Adicet regain compliance with the minimum bid price requirement for continued listing on the Nasdaq Capital Market [6]. Group 3: Company Overview - Adicet Bio, Inc. is a clinical stage biotechnology company focused on developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer [7].